Wednesday, 17 Oct 2018

You are here

SPAR Predicts ILD Progression in Systemic Sclerosis

The development and progression of interstitial lung disease in systemic sclerosis can be an ominous finding. A new analysis of two independent clinical trial cohorts shows that oxygen saturation (SpO2) < 94% after 6 minute walk time (6MWT) and the presence of arthritis predicted the development of ILD in SSc. (SPAR: SPO2 and ARthritis) 

A total of 215 SSc patients with mild ILD (without pulmonary HTN or COPD) were followed prospectively with SpO2 levels, high-resolution computed tomography (HRCT) and pulmonary function tests.

ILD progression was defined as a relative decrease in forced vital capacity (FVC) ≥15%, or FVC ≥10% combined with diffusing capacity for carbon monoxide (DLCO) ≥15% at 1-year.

Between 21-26% of SSc patients showed ILD progression. Independent predictors of progression included lower SpO2 after 6MWT and arthritis.

This SPAR model (SPO2 and ARthritis) increased the prediction rate from 25.5% to 91.7% with an area under the curve of 0.83 (95% CI: 0.73 to 0.93).

These simple measures might be helpful for the risk stratification of SSc patients. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Teenage Obesity Increases Lupus Risk

Analysis of the Black Women's Health Study shows that obesity as a teenager may be associated with increased risk of systemic lupus erythematous (SLE) in adulthood.

The relationship between obesity and SLE risk is unclear. Past studies have predominantly assessed white women, while black women have higher prevalence of both obesity and SLE.

SLE-Scleroderma Overlap Outcomes

Overlap of autoimmune disorders represents a significant diagnostic and management challenge to the rheumatologist. A novel cohort analysis of overlap between systemic sclerosis (SSc) and systemic lupus erythematous (SLE) suggests such patients tend to be younger, more frequently have PAH, but less cutaneous manifestations of SSc.

Excess Mortality in CTD or Systemic Vasculitis Patients

The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.

Mortality Improves in Lupus ESRD

The past two decades have seen a significant decline in mortality among patients with lupus nephritis, U.S. registry data indicated.

Ustekinumab May be Effective in Lupus

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory parameters after 6 months of therapy.